Purpose: We compared the resistance patterns of methicillinresistant Staphylococcus aureus (MRSA) and methicillin-susceptible Staphylococcus aureus (MSSA) keratitis isolates with the common topically applied ophthalmic antimicrobials.
S taphylococcus aureus (SA) is a leading cause of keratitis worldwide. 1, 2 SA is considered the most virulent of all the Staphylococcus species, possessing a multitude of factors that enhance host adhesion, evasion of the human innate immune system, and cytolytic activity against host cells. 3, 4 Approximately one third of the population is colonized with SA, which increases the risk for associated ocular infections. 5, 6 Violation of the epithelial barrier such as using contact lens or other trauma can result in subsequent corneal ulceration, necessitating aggressive treatment with topical antibiotics. 5, 7 SA has emerged as a major threat to public health due to the organism's propensity to develop antibiotic resistance. Historically, SA developed resistance to penicillin G within 2 years of its introduction in 1942. 5 Methicillin was introduced in 1959 to combat the emergence of penicillinase containing SA; however, methicillin-resistant SA (MRSA) was reported only 1 year later. 6 The first case of SA with reduced susceptibilities to vancomycin was reported in 1997, and it has become a more recent concern in the treatment of SA infections. 8 Fortunately, reports of complete vancomycin resistance continue to remain rare. 6 By practical definition, MRSA is resistant to all betalactam antibiotics, including oxacillin, nafcillin, dicloxacillin, and cefazolin, through production of beta-lactamases, mutation of the normal penicillin-binding protein, and/or acquisition of the mecA gene that encodes for an alternative penicillin-binding protein. 5, 9, 10 The increase in MRSA ocular infections resulting in devastating consequences such as corneal perforations, flap melts after refractive surgery, cellulitis, and endophthalmitis has been published. 9, [11] [12] [13] [14] [15] [16] [17] Although these reports are troublesome, studies have suggested that the majority of MRSA ocular manifestations tend not to be visually devastating. 9, 12 Empiric therapy is often initiated before the return of corneal smears and cultures in the treatment of bacterial keratitis. For ulcers less than 2 mm, practitioners may not routinely perform cultures before starting a broad-spectrum antibiotic. 18 Because microbial resistance patterns can vary by year and geographic region, local annual surveys are important in guiding the empiric treatment of bacterial keratitis.
The purpose of this analysis was to compare the prevalence, distribution, and in vitro resistance patterns of MRSA keratitis isolates and methicillin-susceptible SA (MSSA) keratitis isolates with commonly used ophthalmic antimicrobials in a 20-year retrospective review. We hypothesize that MRSA and MSSA will differ in their resistance patterns, and MRSA will have significantly increased resistance to all tested antibiotics in comparison with MSSA with the exception of vancomycin.
MATERIALS AND METHODS
The incidence of bacterial keratitis and the laboratory antibiotic susceptibility patterns of SA keratitis isolates presenting to the Charles T. Campbell Ophthalmic Microbiology Laboratory at the University of Pittsburgh Medical Center (UPMC) over a period of 20 years (January 2, 1993 to November 26, 2012) were reviewed and analyzed. These laboratory data were de-identified and were not from the patients' medical records. The data were used for the calculation of antibiotic susceptibility patterns, which is mandatory for laboratory certification. The laboratory data were reviewed consecutively in reverse chronological order from November 26, 2012 without the use of patient identifiers (University of Pittsburgh, exemption IRB PRO14030138). Cultures positive for SA were defined as significant growth if they were collected from the cornea. Growth collected only from the conjunctiva and/or eyelid were not included in this study.
Methicillin resistance was determined originally with oxacillin and later with cefoxitin using the Kirby-Bauer disk diffusion method [National Committee for Clinical Laboratory and Standards Institute (CLSI), Wayne, PA]. 19 The identification of MRSA using cefoxitin is thought to allow for more sensitive detection of mecA-mediated resistance as compared with oxacillin. 20 In vitro laboratory susceptibility testing of each SA isolate was also performed using the Kirby-Bauer disk diffusion method to bacitracin, cefazolin, ciprofloxacin, gatifloxacin, gentamicin, moxifloxacin, ofloxacin, polymyxin B, sulfamethoxazole, tobramycin, and trimethoprim. 19 Isolates identified as intermediate were considered susceptible to all antibiotics with the exception of cefoxitin and polymyxin B, for which the isolates of intermediate susceptibility were grouped with the resistant isolates. Isolates with intermediate susceptibility to cefoxitin may indicate the presence of the mecA gene, and thus were best classified as cefoxitin resistant. [18] [19] [20] Polymyxin B is considered as a gram-negative antibiotic that does not diffuse well in the medium, and resistance to this antibiotic is characteristic of SA. [18] [19] [20] Thus, intermediate susceptible isolates were categorized as polymyxin B resistant.
Besifloxacin was not tested for in vitro susceptibility because there is a lack of a susceptibility standard and commercial source for disks and powder. Cefazolin susceptibility was tested because the literature does demonstrate MRSA susceptibility to cephalosporin antibiotics. [21] [22] [23] [24] It must be noted that there are no susceptibility standards for topical therapy. The serum standards can be used with the assumption that antibiotic concentrations in the ocular tissue are equal to or greater than the concentration of antibiotics in the serum. This likely allows for the overreporting of resistance.
All statistical analyses of in vitro susceptibility results of MSSA and MRSA were performed using x 2 test (MiniTab, State College, PA and SPSS, IBM Corp 2011; Version 20, Armonk, NY). Differences between SA resistance rates between the first and second decades of the study were determined by the Fisher exact test (SPSS). P # of 0.05 was considered to be statistically significant for all analyses performed. Figure 1 illustrates the distribution of bacterial keratitis from January 1993 to November 2012 (N = 1576). Overall, there were more gram-positive organisms (54%, 869 of 1576 isolates) than gram-negative organisms (46%, 729 of 1576 isolates). However, there was no statistically significant difference between the incidences of gram-negative and gram-positive infections (P = 0.346, x 2 ). SA (25.2%) was found to be the most common cause of bacterial keratitis.
RESULTS
More SA isolates were susceptible to the nonfluoroquinolones compared with the fluoroquinolones (P , 0.05, x 2 ). In addition, more SA isolates were resistant to tobramycin (95 of 398 SA isolates) compared with gentamicin (23 of 398 SA isolates) (P = 0.0001, x 2 ), whereas susceptibilities to bacitracin (95.2%), gentamicin (94.2%), sulfamethoxazole (97.4%), and trimethoprim (95.7%) were statistically equivalent (P = 0.176, x 2 ). All SA isolates were susceptible to vancomycin.
The 398 SA isolates were further subdivided into 2 categories: MSSA and MRSA. There was a total of 122 MRSA isolates that represented 30.7% (122 of 398) of the total SA isolates and 7.7% (122 of 1576) of the total bacterial isolates. Table 1 lists the prevalence of MRSA in the 4-year interval from 1993 to 2012. The ratio of MSSA to MRSA changed from more than 4:1 to less than 2:1 from the first 4 years (1993) (1994) (1995) (1996) to the last 4 years (2009-2012) of the study period. There was a statistically significant increase in the prevalence of MRSA keratitis over time (P = 0.001, x 2 ).
The overall resistances of MRSA and MSSA to the aforementioned antibiotics during the study period are listed in Table 2 . As shown, a significantly greater number of MRSA isolates was found to be resistant to all antibiotics tested compared with MSSA (P , 0.05, x 2 ), with the exclusion of polymyxin B (resistant to all) and vancomycin (susceptible to all).
MSSA
MSSA retained more than 90% susceptibility to all antibiotics tested over the study period. There was no significant difference between percent susceptibilities to bacitracin (97.8%), cefazolin (99.3%), gentamicin (97.8%), sulfamethoxazole (98.9%), and trimethoprim (98.9%) (P = 0.137, x 2 ). A significantly greater number of MSSA isolates was found to be resistant to the fluoroquinolones compared with the nonfluoroquinolones (P , 0.05, x 2 ); however, no difference was detected between the second-generation and fourth-generation fluoroquinolones (P = 0.173, x 2 ). There was a significant increase in resistance from the first to the second decade of the study period for ofloxacin (P = 0.003, Fisher exact test), gatifloxacin (P = 0.044, Fisher exact test), and moxifloxacin (P = 0.001, Fisher exact test).
MRSA
Besides vancomycin, MRSA retained the best susceptibilities to sulfamethoxazole (94.3%), bacitracin (89.3%), trimethoprim (88.5%), and gentamicin (86.1%). No significant difference between percent resistances of MRSA to these 4 antibiotics was detected (P . 0.05, x 2 ). There was greater resistance against the fluoroquinolones compared with the nonfluoroquinolones (P , 0.05, x 2 ). Unlike MSSA, MRSA was found to be significantly more resistant to the secondgeneration compared with the fourth-generation fluoroquinolones (P = 0.0001, x 2 ). A significant increase in resistance between the first and second decades of the study for moxifloxacin (P = 0.022, Fisher exact test) and gatifloxacin (P = 0.045, Fisher exact test) was detected.
DISCUSSION
Whether methicillin resistance confers greater virulence to SA is a topic of hot debate in the general medical literature. 6, [25] [26] [27] Community-acquired MRSA (CA-MRSA) can produce Panton-Valentine leukocidin (PVL), alpha toxin, and phenol-soluble modulins (PSMs), which may exacerbate ocular inflammation. 1, 2, 6, 28 However, reports suggest that the majority of ocular MRSA infections are equivocal to MSSA in terms of complication rates and final visual outcomes. 3, 4, 11, 20, 29, 30 Furthermore, the clinical virulence of MRSA is likely overrepresented in the literature because only the more serious infections are cultured and reported. 5, 6, 12, 25, 26 Vancomycin is widely regarded as the gold standard in the treatment of MRSA keratitis. 5, 7, 12, 18, 20, 26, 31 However, as a fortified antibiotic, vancomycin is far from ideal given its cost, toxicity, short half-life, and the need for refrigeration. Additionally, vancomycin is considered less bactericidal in comparison with the beta-lactams, which may have important clinical implications with regard to the emergence of MRSA with reduced glycopeptide susceptibilities. 5, 32 Although the risk of systemic resistance from topical antimicrobials is likely minimal, increased extraocular resistance has been reported with the use of topical tetracycline in the treatment of trachoma. 6, 33 Fortunately, no culture-proven vancomycinresistant SA (VRSA) has been reported in the ophthalmic literature thus far. 8, 34 In our review, the prevalence of MRSA keratitis increased during the study period, consistent with the reports worldwide. 2, 6, 9, 17, 35 MRSA retained better in vitro susceptibilities to sulfamethoxazole, bacitracin, gentamicin, and trimethoprim in comparison with the fluoroquinolones. Surprisingly, MRSA had lower susceptibility to gentamicin than anticipated (85.94%), as a survey from 1993 to 2010 published at the same institution showed 100% susceptibility to gentamicin for 9 MRSA isolates. 18 In a review of the literature, ocular MRSA susceptibility rates tended to vary, although susceptibility to sulfamethoxazole/trimethoprim was generally reported to be high (greater than 90%), which was consistent with our findings. 5, 9, [11] [12] [13] [14] [15] [16] [17] 29 However, some studies reported lower MRSA susceptibility rates to sulfamethoxazole/trimethoprim, ranging from 66.6% to 80%. 9, 11, 12, 16, 20, 36 We believe that these differences reflect regional and population variations and recognize that our results may differ from other studies. Increased microbial resistance to fluoroquinolones, the most commonly used empiric monotherapy in the treatment of bacterial keratitis, has been widely reported. 1, 18, 20, 31, [37] [38] [39] In our review, the overall susceptibilities to the fluoroquinolones were poor. Figure 2 demonstrates increasing trends in MSSA and MRSA resistances to the fluoroquinolones during the study period. A greater number of MRSA isolates, as seen in Figure 2 , were resistant to the fluoroquinolones compared with MSSA (P = 0.001, x 2 ). For MRSA, overall resistance rates remained higher against the "older" fluoroquinolones (ciprofloxacin and ofloxacin) compared with the "newer" fluoroquinolones (moxifloxacin and gatifloxacin). Secondgeneration fluoroquinolones are smaller, more hydrophobic, and less soluble, allowing for easier efflux out of the microorganism. 35 Furthermore, only 1 mutation (against gyrase) is needed for resistance against the secondgeneration fluoroquinolones, whereas 2 mutations (against gyrase and topoisomerase IV) are needed to confer resistance against fourth-generation fluoroquinolones. 18, 40 Interestingly, an increase in the resistance rates during the study period was found for the fourth-generation fluoroquinolones for both MSSA and MRSA (P , 0.05, Fisher exact test). Previous use of topical fluoroquinolones has been associated with increased in vitro resistance. 41 These results likely reflect on the increasing popularity of moxifloxacin and gatifloxacin, since their introduction in 2003, in the empiric treatment of bacterial keratitis. 37, 39 We postulate that antibiotics such as trimethoprim, sulfamethoxazole, bacitracin, and gentamicin possess better susceptibility profiles since they remain less popular compared with the fluoroquinolones.
Low levels of in vitro resistance against an antiinfective do not necessarily correlate with poor clinical efficacy. Antibiotic concentrations are much higher in ocular tissue by topical therapy in comparison with systemic therapy. 42 Since the susceptibility and resistance patterns of the aforementioned antibiotics were determined using systemic standards, there is likely an overestimation of laboratory resistance rates. Furthermore, in vitro studies do not take into account pharmacokinetics such as the excellent corneal penetration of fourth-generation fluoroquinolones. 43 Additional limitations include that as an in vitro study, dosing, local immunity, and patient compliance are not taken into account. However, in vitro studies are considered the standard in determining antibiotic resistances. With the introduction of broad-spectrum antibiotics such as the fluoroquinolones, community ophthalmologists are more comfortable in empirically treating smaller ulcers without laboratory support. This likely contributed to the decline in the number of corneal cultures sent to UPMC, a tertiary referral center, through the years. Thus, a selection bias for the larger and more clinically aggressive isolates may have resulted. Despite this, we believe that our results, which showed increasing MRSA prevalence and antimicrobial resistance, are comparable with the worldwide literature. Further studies are needed, however, to determine the clinical relevance of these laboratory findings.
In conclusion, empiric antimicrobial selection should be guided by annual regional surveillance surveys, and therapy should be optimized by laboratory susceptibilities and clinical response in the treatment of bacterial keratitis. Our data support the hypothesis that MRSA and MSSA differ in their resistance patterns. MRSA isolates have significantly increased resistance to all tested antibiotics in comparison with MSSA, with the exception of polymyxin B and vancomycin. Finally, although vancomycin is our first-line choice of treatment in cases of MRSA keratitis, our results suggest that other commonly used topical antibiotics such as sulfamethoxazole, trimethoprim, gentamicin, and bacitracin ointment may be adjunctively considered with the guidance of laboratory support. The empiric use of second-generation fluoroquinolone antiinfectives in the treatment of MRSA keratitis should be avoided.
